# Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.

> **NCT04552600** · PHASE1,PHASE2 · COMPLETED · sponsor: **Natureceuticals Sdn Bhd** · enrollment: 100 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Nuvastatic
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04552600
- **Lead sponsor:** Natureceuticals Sdn Bhd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2022-08-10
- **Final completion:** 2022-08-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552600, "Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT04552600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*